{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:10:18Z","timestamp":1790709018642,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014064","name":"Universidad de Salamanca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014064","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.biopha.2022.113276","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T23:08:38Z","timestamp":1655334518000},"page":"113276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effect of sarpogrelate treatment on 5-HT modulation of vascular sympathetic innervation and platelet activity in diabetic rats"],"prefix":"10.1016","volume":"153","author":[{"given":"Juan Francisco","family":"Fern\u00e1ndez-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Garc\u00eda-Pedraza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mar\u00edn-Qu\u00edlez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Bastida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asunci\u00f3n","family":"Mor\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Garc\u00eda-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113276_bib1","series-title":"IDF Diabetes Atlas","first-page":"31","article-title":"Chapter 3: The global picture","author":"International Diabetes Federation","year":"2021"},{"key":"10.1016\/j.biopha.2022.113276_bib2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12883-018-1125-1","article-title":"Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients","volume":"18","author":"Mo\u0163\u0103\u0163\u0103ianu","year":"2018","journal-title":"BMC Neurol."},{"key":"10.1016\/j.biopha.2022.113276_bib3","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.3390\/ijms20246345","article-title":"Coagulatory defects in Type-1 and Type-2 diabetes","volume":"20","author":"Sobczak","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113276_bib4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s13300-019-0612-8","article-title":"Cardiovascular risk in Type 1 diabetes mellitus","volume":"10","author":"Schofield","year":"2019","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.biopha.2022.113276_bib5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.00007.2009","article-title":"Sympathetic nervous system overactivity and its role in the development of cardiovascular disease","volume":"90","author":"Malpas","year":"2010","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biopha.2022.113276_bib6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/biomedicines9081007","article-title":"Clinical relevance of the sympathetic-vascular interactions in health and disease","volume":"9","author":"Quarti-Trevano","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2022.113276_bib7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1034\/j.1600-0609.2000.065006357.x","article-title":"Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo","volume":"65","author":"von K\u00e4nel","year":"2000","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.biopha.2022.113276_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00002727-200404000-00003","article-title":"Pathophysiology of diabetes mellitus","volume":"27","author":"Guthrie","year":"2004","journal-title":"Crit. Care Nurs. Q."},{"key":"10.1016\/j.biopha.2022.113276_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jez.2554","article-title":"Cardiovascular serotonergic system: evolution, receptors, transporter, and function","volume":"337","author":"Soslau","year":"2022","journal-title":"J. Exp. Zool. A Ecol. Integr. Physiol."},{"key":"10.1016\/j.biopha.2022.113276_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/09537104.2018.1478072","article-title":"Autocrine and paracrine regulatory functions of platelet serotonin","volume":"29","author":"Mammadova-Bach","year":"2018","journal-title":"Platelets"},{"key":"10.1016\/j.biopha.2022.113276_bib11","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1210\/en.2016-1839","article-title":"The diverse metabolic roles of peripheral serotonin","volume":"158","author":"Martin","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2022.113276_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.acvd.2016.08.002","article-title":"Cardiovascular remodeling and the peripheral serotonergic system","volume":"110","author":"Ayme-Dietrich","year":"2017","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.biopha.2022.113276_bib13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.bjp.0706216","article-title":"Diabetes-induced changes in the 5-hydroxytryptamine inhibitory receptors involved in the pressor effect elicited by sympathetic stimulation in the pithed rat","volume":"145","author":"Garc\u00eda","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113276_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120335","article-title":"Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes","volume":"293","author":"Garc\u00eda-Pedraza","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2022.113276_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejphar.2013.05.045","article-title":"Peripheral 5-HT1D and 5-HT7 serotonergic receptors modulate sympathetic neurotransmission in chronic sarpogrelate treated rats","volume":"714","author":"Garc\u00eda-Pedraza","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113276_bib16","doi-asserted-by":"crossref","first-page":"33979","DOI":"10.1038\/srep33979","article-title":"Blocking 5-HT2 receptor restores cardiovascular disorders in type 1 experimental diabetes","volume":"6","author":"Garc\u00eda-Pedraza","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113276_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jphs.2021.05.008","article-title":"Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment","volume":"147","author":"Garc\u00eda-Pedraza","year":"2021","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2022.113276_bib18","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1055\/s-0041-1723987","article-title":"Characterization of the platelet phenotype caused by a germline RUNX1 variant in a CRISPR\/Cas9-generated murine model","volume":"121","author":"Mar\u00edn-Qu\u00edlez","year":"2021","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.biopha.2022.113276_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002289","article-title":"Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes","volume":"9","author":"Bjerre-Christensen","year":"2021","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.biopha.2022.113276_bib20","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/HYPERTENSIONAHA.121.17981","article-title":"Hypertension in diabetes: an update of basic mechanisms and clinical disease","volume":"78","author":"Jia","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2022.113276_bib21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.diabet.2020.09.001","article-title":"Cardiovascular disease in type 1 diabetes: a review of epidemiological data and underlying mechanisms","volume":"46","author":"Verg\u00e8s","year":"2020","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.biopha.2022.113276_bib22","doi-asserted-by":"crossref","first-page":"19358","DOI":"10.1038\/s41598-020-76298-6","article-title":"Role of peripheral 5-HT5A receptors in 5-HT-induced cardiac sympatho-inhibition in type 1 diabetic rats","volume":"10","author":"Garc\u00eda-Pedraza","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113276_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF02341500","article-title":"Alloxan: history and mechanism of action","volume":"31","author":"Lenzen","year":"1988","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2022.113276_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1024762002836","article-title":"Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats","volume":"249","author":"Umrani","year":"2003","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.biopha.2022.113276_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2014.02.043","article-title":"The role of endothelium-derived hyperpolarizing factor and cyclooxygenase pathways in the inhibitory serotonergic response to the pressor effect elicited by sympathetic stimulation in chronic sarpogrelate treated rats","volume":"731","author":"Garc\u00eda-Pedraza","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113276_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0021-9150(03)00054-6","article-title":"Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism","volume":"168","author":"Hayashi","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2022.113276_bib27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/FJC.0b013e3180325af3","article-title":"Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease","volume":"49","author":"Miyazaki","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113276_bib28","first-page":"75","article-title":"Effect of sarpogrelate on cardiovascular disorders","volume":"16","author":"Shikata","year":"2011","journal-title":"Exp. Clin. Cardiol."},{"key":"10.1016\/j.biopha.2022.113276_bib29","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/1074248410384708","article-title":"Mechanism of sarpogrelate action in improving cardiac function in diabetes","volume":"16","author":"Goyal","year":"2011","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113276_bib30","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.bjp.0701714","article-title":"Characterization of prejunctional 5-HT1 receptors that mediate the inhibition of pressor effects elicited by sympathetic stimulation in the pithed rat","volume":"123","author":"Mor\u00e1n","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113276_bib31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejphar.2010.06.013","article-title":"Pharmacological profile of 5-hydroxytryptamine-induced inhibition on the pressor effect elicited by sympathetic stimulation in long-term diabetic pithed rats","volume":"643","author":"Mor\u00e1n","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113276_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/CIRCRESAHA.116.306531","article-title":"Thirty years of saying NO: sources, fate, actions, and misfortunes of the endothelium-derived vasodilator mediator","volume":"119","author":"Vanhoutte","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2022.113276_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1527-3466.2004.tb00130.x","article-title":"Therapeutic potentials of sarpogrelate in cardiovascular disease","volume":"22","author":"Saini","year":"2004","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.biopha.2022.113276_bib34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/01.mbc.0000176197.48134.08","article-title":"5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes","volume":"16","author":"Nomura","year":"2005","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.biopha.2022.113276_bib35","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.pharmthera.2005.12.004","article-title":"5-hydroxytryptamine receptors in the human cardiovascular system","volume":"111","author":"Kaumann","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113276_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2004.08.005","article-title":"Functions of 5-HT2A receptor and its antagonists in the cardiovascular system","volume":"104","author":"Nagatomo","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113276_bib37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijcard.2009.09.539","article-title":"Sarpogrelate protects against high glucose-induced endothelial dysfunction and oxidative stress","volume":"147","author":"Sun","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.113276_bib38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000105135","article-title":"Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study","volume":"24","author":"Uchiyama","year":"2007","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.biopha.2022.113276_bib39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0024-3205(94)00407-J","article-title":"Effect of streptozotocin-induced diabetes mellitus on serotonin measures of peripheral tissues in rats","volume":"56","author":"Mart\u00edn","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2022.113276_bib40","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1517\/13543784.12.5.805","article-title":"The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation","volume":"12","author":"Doggrell","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2022.113276_bib41","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1517\/13543784.13.7.865","article-title":"Sarpogrelate: cardiovascular and renal clinical potential","volume":"13","author":"Doggrell","year":"2004","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2022.113276_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.12.011","article-title":"Effect of sarpogrelate, a selective 5-HT(2A) receptor antagonist, on characteristics of coronary artery disease in patients with type 2 diabetes","volume":"257","author":"Lee","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2022.113276_bib43","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2176\/nmc.53.291","article-title":"Sarpogrelate dilates cerebral arteries in the absence of exogenous serotonin","volume":"53","author":"Kawamura","year":"2013","journal-title":"Neurol. Med. Chir."},{"key":"10.1016\/j.biopha.2022.113276_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5761\/atcs.oa.12.02061","article-title":"Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans","volume":"19","author":"Ren","year":"2013","journal-title":"Ann. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.biopha.2022.113276_bib45","first-page":"189","article-title":"Binding affinity of sarpogrelate, a new antiplatelet agent, and its metabolite for serotonin receptor subtypes","volume":"331","author":"Nishio","year":"1996","journal-title":"Arch. Int. Pharmacodyn. Ther."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222006655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222006655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:15:06Z","timestamp":1779966906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222006655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":45,"alternative-id":["S0753332222006655"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113276","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of sarpogrelate treatment on 5-HT modulation of vascular sympathetic innervation and platelet activity in diabetic rats","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113276"}}